SCHEMBL5844174

SCHEMBL5844174

COC(=O)Cc1ccc(CCCNS(C)(=O)=O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.59
CYP4F2 P78329 1/20 0.57
CYP4A11 Q02928 1/20 0.57
CA12 O43570 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A1 P00352 3/20 0.42
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
GAA P10253 2/20 0.41
GFER P55789 1/20 0.41
TLR7 Q9NYK1 2/20 0.40
KDM4E B2RXH2 1/20 0.40
NPC1 O15118 1/20 0.40
HPGD P15428 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5726946 0.91 CYP4F2 (0.60) POLBCYP4F2CYP4A11CA12CA7
SCHEMBL5725343 0.86 POLB (0.57) POLBCYP4F2CYP4A11CA12CA7
SCHEMBL5844585 0.84 POLB (0.68) POLBKMT2AALDH1A1OPRM1OPRD1
SCHEMBL11493064 0.82 CYP4A11 (0.75) CYP4F2CYP4A11KMT2AALDH1A1GAA
SCHEMBL15586041 0.82 CYP4A11 (0.75) CYP4F2CYP4A11KMT2AALDH1A1GAA
SCHEMBL5843449 0.81 KMT2A (0.60) POLBCYP4F2CYP4A11CA12CA7
SCHEMBL5725843 0.79 POLB (0.53) POLBCYP4F2CYP4A11CA12CA7
SCHEMBL7921017 0.78 ALDH1A1 (0.60) CYP4F2CYP4A11KMT2AALDH1A1GAA
SCHEMBL7039947 0.78 CYP4A11 (0.55) CYP4F2CYP4A11KMT2AALDH1A1GAA
SCHEMBL11113227 0.78 CYP4Z1 (0.48) POLBCYP4F2CYP4A11CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6992193-B2 Sulfonylamino phenylacetamide derivatives and methods of their use ADOLOR CORPORATION (US) 2006-01-31 US disclosed
WO-2005004796-A2 SULFONYLAMINO PHENYLACETAMIDE DERIVATIVES AND METHODS OF THEIR USE ADOLOR CORPORATION (US) 2005-01-20 WO disclosed
US-20040254156-A1 Sulfonylamino phenylacetamide derivatives and methods of their use CALIXA THERAPEUTICS, INC. 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254156-A1 Sulfonylamino phenylacetamide derivatives and methods of their use CYP2E1, CYP2D6, CYP3A43 POLB 3233/4885CYP4F2 44/4885CYP4A11 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.